Affimed Nv Stock Today

AFMD Stock  USD 2.62  0.02  0.76%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 84

 
High
 
Low
Very High
Affimed NV is trading at 2.62 as of the 24th of November 2024, a 0.76 percent down since the beginning of the trading day. The stock's lowest day price was 2.61. Affimed NV has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Affimed NV are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of August 2024 and ending today, the 24th of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
12th of September 2014
Category
Healthcare
Classification
Health Care
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany. Affimed NV operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 16.39 M outstanding shares of which 982.93 K shares are presently shorted by private and institutional investors with about 12.46 trading days to cover. More on Affimed NV

Moving together with Affimed Stock

  0.72VALN Valneva SE ADRPairCorr

Moving against Affimed Stock

  0.6KZR Kezar Life SciencesPairCorr
  0.34MLYS Mineralys Therapeutics,PairCorr

Affimed Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEOAdi Hoess
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.08090.0852
Notably Down
Pretty Stable
Total Current Liabilities28.4 M25.9 M
Significantly Up
Slightly volatile
Non Current Liabilities Total23.3 M13.4 M
Way Up
Slightly volatile
Total Assets105.8 M97.2 M
Significantly Up
Slightly volatile
Total Current Assets98.5 M84.2 M
Fairly Up
Slightly volatile
Debt Levels
Affimed NV can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Affimed NV's financial leverage. It provides some insight into what part of Affimed NV's total assets is financed by creditors.
Liquidity
Affimed NV currently holds 19.35 M in liabilities with Debt to Equity (D/E) ratio of 0.1, which may suggest the company is not taking enough advantage from borrowing. Affimed NV has a current ratio of 4.8, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Affimed NV's use of debt, we should always consider it together with its cash and equity.

Change To Inventory

105,000
Affimed NV (AFMD) is traded on NASDAQ Exchange in USA. It is located in Gottlieb-Daimler-Straße 2, Mannheim, Germany, 68165 and employs 76 people. Affimed NV is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 42.95 M. Affimed NV conducts business under Biotechnology sector and is part of Health Care industry. The entity has 16.39 M outstanding shares of which 982.93 K shares are presently shorted by private and institutional investors with about 12.46 trading days to cover. Affimed NV currently holds about 237.23 M in cash with (110.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.59.
Check Affimed NV Probability Of Bankruptcy
Ownership Allocation
Affimed NV holds a total of 16.39 Million outstanding shares. 30% of Affimed NV outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Affimed Ownership Details

Affimed Stock Institutional Holders

InstituionRecorded OnShares
State Street Corp2024-06-30
55.1 K
Walleye Trading Advisors, Llc2024-06-30
24.1 K
Commonwealth Equity Services Inc2024-06-30
21.6 K
Abrdn Plc2024-09-30
20.9 K
Dimensional Fund Advisors, Inc.2024-09-30
18.1 K
Fmr Inc2024-09-30
17.7 K
Blackrock Inc2024-06-30
16.3 K
Clayton Financial Group Llc2024-06-30
15 K
Cubist Systematic Strategies, Llc2024-09-30
14 K
683 Capital Management Llc2024-09-30
650 K
Morgan Stanley - Brokerage Accounts2024-06-30
559.6 K
View Affimed NV Diagnostics

Affimed NV Historical Income Statement

At present, Affimed NV's Research Development is projected to increase significantly based on the last few years of reporting. The current year's Income Tax Expense is expected to grow to 3,150, whereas Selling General Administrative is forecasted to decline to about 13.8 M. View More Fundamentals

Affimed Stock Against Markets

Affimed NV Corporate Management

Uwe ReuschHead CultureProfile
Denise MuellerChief BoardProfile
RPh PharmDChief OfficerProfile
Arndt MDChief BoardProfile
Angus SmithCFO BoardProfile
Michael WolfHead AdministrationProfile
Andreas MDChief BoardProfile

Already Invested in Affimed NV?

The danger of trading Affimed NV is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Affimed NV is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Affimed NV. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Affimed NV is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Affimed NV is a strong investment it is important to analyze Affimed NV's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Affimed NV's future performance. For an informed investment choice regarding Affimed Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Affimed NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade Affimed Stock refer to our How to Trade Affimed Stock guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Affimed NV. If investors know Affimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Affimed NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.76)
Revenue Per Share
0.493
Quarterly Revenue Growth
(0.90)
Return On Assets
(0.49)
Return On Equity
(1.24)
The market value of Affimed NV is measured differently than its book value, which is the value of Affimed that is recorded on the company's balance sheet. Investors also form their own opinion of Affimed NV's value that differs from its market value or its book value, called intrinsic value, which is Affimed NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Affimed NV's market value can be influenced by many factors that don't directly affect Affimed NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Affimed NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if Affimed NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Affimed NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.